129 related articles for article (PubMed ID: 11420460)
21. [Radical cystectomy for superficial tumors in the BCG era].
Huguet Pérez J; Palou J; Millán Rodríguez F; Villavicencio Mavrich H; Rodríguez JV
Arch Esp Urol; 2002; 55(1):50-6. PubMed ID: 11957752
[TBL] [Abstract][Full Text] [Related]
22. Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment.
Ick K; Schultz M; Stout P; Fan K
Urology; 1997 Apr; 49(4):541-6; discussion 546-7. PubMed ID: 9111623
[TBL] [Abstract][Full Text] [Related]
23. Stromal invasion of the prostate following a complete response to bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the ureter and the bladder.
Hara I; Yao A; Muramaki M; Hikosaka S; Yamada Y; Kawabata G; Kamidono S
Int J Urol; 2004 Apr; 11(4):250-2. PubMed ID: 15028107
[TBL] [Abstract][Full Text] [Related]
24. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
[TBL] [Abstract][Full Text] [Related]
25. [A case of transitional cell carcinoma with squamous differentiation which developed squamous cell carcinoma in situ in the clinical course].
Sugiura S; Makiyama K; Yokomizo Y; Umemoto S; Miyoshi Y; Nakaigawa N; Ogawa T; Uemurai H; Yao M; Kubota Y; Yamanaka S
Hinyokika Kiyo; 2006 Sep; 52(9):715-8. PubMed ID: 17040058
[TBL] [Abstract][Full Text] [Related]
26. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
27. Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can post-induction random bladder biopsies be avoided?
Smith PJ; Lotan Y; Raj GV; Sagalowsky AI; Margulis V
Cytopathology; 2014 Apr; 25(2):108-11. PubMed ID: 23551700
[TBL] [Abstract][Full Text] [Related]
28. [Clinical study of primary carcinoma in situ of the bladder].
Mori Y; Shima H; Ihara H; Yabumoto H; Taguchi K; Koike H; Nojima M; Yamamoto H; Ikoma F
Hinyokika Kiyo; 1996 Jan; 42(1):17-21. PubMed ID: 8686577
[TBL] [Abstract][Full Text] [Related]
29. BCG in management of transitional cell carcinoma invasive to prostate.
Siami P; Chinn S; Clayton M; Ray V; Rubenstein M; Guinan P
Urology; 1989 Dec; 34(6):381-2. PubMed ID: 2595884
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.
Takenaka A; Yamada Y; Miyake H; Hara I; Fujisawa M
Int J Urol; 2008 Apr; 15(4):309-13. PubMed ID: 18380817
[TBL] [Abstract][Full Text] [Related]
31. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
32. [Squamous cell carcinoma of the urinary bladder after intravesical bacillus Calmette-Guerin therapy for carcinoma in situ: a case report].
Uemura M; Nishimura K; Nakagawa M; Kanno N; Miyoshi S; Kawano K; Inoue H
Hinyokika Kiyo; 2004 Nov; 50(11):809-11. PubMed ID: 15628544
[TBL] [Abstract][Full Text] [Related]
33. [The significance of bacillus Calmette-Guerin in the therapy of carcinoma in situ of the bladder].
Kurozumi T; Koikawa Y; Yagi H; Omoto T; Iwata Y
Nihon Hinyokika Gakkai Zasshi; 1991 Jun; 82(6):900-6. PubMed ID: 1881009
[TBL] [Abstract][Full Text] [Related]
34. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
35. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
Eure GR; Cundiff MR; Schellhammer PF
J Urol; 1992 Feb; 147(2):376-9. PubMed ID: 1732597
[TBL] [Abstract][Full Text] [Related]
36. Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors.
Herr HW; Pinsky CM; Whitmore WF; Sogani PG; Oettgen HF; Melamed MR
Urology; 1985 Feb; 25(2):119-23. PubMed ID: 3881870
[TBL] [Abstract][Full Text] [Related]
37. [T1 G3 bladder tumors: the respective role of BCG and cystectomy].
Pfister C; Landé P; Hervé JM; Barré P; Barbagelatta M; Camey M; Botto H
Prog Urol; 1995 Apr; 5(2):231-7. PubMed ID: 7719369
[TBL] [Abstract][Full Text] [Related]
38. [Prostatic involvement by urothelial carcinoma in patients with bladder cancer and their implications in the clinical practice].
Huguet J
Actas Urol Esp; 2012 Oct; 36(9):545-53. PubMed ID: 22520044
[TBL] [Abstract][Full Text] [Related]
39. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
40. [Muscularis mucosae invasion: prognostic factor for intravesical BCG immunotherapy failure for T1 bladder carcinoma].
Nguyen-Huu Y; Delorme G; Lillaz J; Bedgedjian I; Le Ray-Ferrières I; Chabannes E; Bernardini S; Guichard G; Bittard H; Kleinclauss F
Prog Urol; 2012 May; 22(5):284-90. PubMed ID: 22515925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
